ABCB4 Gene Cholestasis Intrahepatic of Pregnancy Type 3 Genetic Test
Test Name: ABCB4 Gene Cholestasis Intrahepatic of Pregnancy Type 3 Genetic Test
Components: Blood
Price: 3200.0 AED
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Metabolic Disorders
Doctor: General Physician
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for ABCB4 Gene Cholestasis Intrahepatic of Pregnancy Type 3 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with Cholestasis Intrahepatic of Pregnancy Type 3.
Test Details
ABCB4 gene cholestasis intrahepatic of pregnancy type 3 is a genetic disorder that affects the liver during pregnancy. It is caused by mutations in the ABCB4 gene, which is responsible for the production of a protein called multidrug resistance protein 3 (MDR3). MDR3 is involved in the transport of certain fats called phospholipids from liver cells into bile, which is necessary for normal bile flow.
Mutations in the ABCB4 gene can lead to reduced or absent MDR3 protein function, resulting in impaired phospholipid transport and accumulation of toxic bile acids in liver cells. This can cause inflammation and damage to the liver, leading to symptoms such as itching, jaundice, and elevated liver enzymes.
NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that uses advanced sequencing technologies to rapidly and simultaneously analyze multiple genes or the entire genome. In the case of ABCB4 gene cholestasis intrahepatic type 3, NGS genetic testing can identify specific mutations in the ABCB4 gene that are associated with the disorder.
NGS genetic testing for ABCB4 gene cholestasis intrahepatic type 3 can be used for diagnostic purposes to confirm the presence of mutations in affected individuals. It can also be used for carrier testing to determine if individuals carry a single copy of the mutated gene and may be at risk of passing it on to their children.
This type of genetic testing can provide valuable information for healthcare providers to better understand the underlying cause of the disorder, make an accurate diagnosis, and provide appropriate management and treatment options for affected individuals.
| Test Name | ABCB4 Gene Cholestasis intrahepatic of pregnancy type 3 Genetic Test |
|---|---|
| Components | |
| Price | 3200.0 AED |
| Sample Condition | Blood |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Metabolic Disorders |
| Doctor | General Physician |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for ABCB4 Gene Cholestasis intrahepatic, of pregnancy, type 3 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with Cholestasis intrahepatic, of pregnancy, type 3 |
| Test Details |
ABCB4 gene cholestasis intrahepatic, of pregnancy, type 3 is a genetic disorder that affects the liver during pregnancy. It is caused by mutations in the ABCB4 gene, which is responsible for the production of a protein called multidrug resistance protein 3 (MDR3). MDR3 is involved in the transport of certain fats called phospholipids from liver cells into bile, which is necessary for normal bile flow. Mutations in the ABCB4 gene can lead to reduced or absent MDR3 protein function, resulting in impaired phospholipid transport and accumulation of toxic bile acids in liver cells. This can cause inflammation and damage to the liver, leading to symptoms such as itching, jaundice, and elevated liver enzymes. NGS (Next-Generation Sequencing) genetic testing is a type of genetic test that uses advanced sequencing technologies to rapidly and simultaneously analyze multiple genes or the entire genome. In the case of ABCB4 gene cholestasis intrahepatic, type 3, NGS genetic testing can identify specific mutations in the ABCB4 gene that are associated with the disorder. NGS genetic testing for ABCB4 gene cholestasis intrahepatic, type 3 can be used for diagnostic purposes to confirm the presence of mutations in affected individuals. It can also be used for carrier testing to determine if individuals carry a single copy of the mutated gene and may be at risk of passing it on to their children. This type of genetic testing can provide valuable information for healthcare providers to better understand the underlying cause of the disorder, make an accurate diagnosis, and provide appropriate management and treatment options for affected individuals. |
